Bighetti, Bruna; Donnarumma, Carlos Del Cistia; Esper, Rodrigo Barbosa; Vital, Carolina Graziani; Morikawa, Aleksandra Tiemi; Oliveira, José Salvador Rodrigues de; Maranhão, Raul Cavalcante 
; Forones, Nora Manoukian
Source: Journal of Oncology Research and Therapy. Unidade: FCF
Subjects: ADENOCARCINOMA, NANOPARTÍCULAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BIGHETTI, Bruna et al. Use of paclitaxel associated to lipid core nanoparticles (LDE) in the second or third line treatment of advanced pancreatic adenocarcinoma. Journal of Oncology Research and Therapy, v. 8, p. 1-7, 2023Tradução . . Disponível em: https://dx.doi.org/10.29011/2574-710X.10192. Acesso em: 11 jun. 2024.APA
Bighetti, B., Donnarumma, C. D. C., Esper, R. B., Vital, C. G., Morikawa, A. T., Oliveira, J. S. R. de, et al. (2023). Use of paclitaxel associated to lipid core nanoparticles (LDE) in the second or third line treatment of advanced pancreatic adenocarcinoma. Journal of Oncology Research and Therapy, 8, 1-7. doi:10.29011/2574-710X.10192NLM
Bighetti B, Donnarumma CDC, Esper RB, Vital CG, Morikawa AT, Oliveira JSR de, Maranhão RC, Forones NM. Use of paclitaxel associated to lipid core nanoparticles (LDE) in the second or third line treatment of advanced pancreatic adenocarcinoma [Internet]. Journal of Oncology Research and Therapy. 2023 ; 8 1-7.[citado 2024 jun. 11 ] Available from: https://dx.doi.org/10.29011/2574-710X.10192Vancouver
Bighetti B, Donnarumma CDC, Esper RB, Vital CG, Morikawa AT, Oliveira JSR de, Maranhão RC, Forones NM. Use of paclitaxel associated to lipid core nanoparticles (LDE) in the second or third line treatment of advanced pancreatic adenocarcinoma [Internet]. Journal of Oncology Research and Therapy. 2023 ; 8 1-7.[citado 2024 jun. 11 ] Available from: https://dx.doi.org/10.29011/2574-710X.10192
